Novartis launches Nerve platform to harness ‘data revolution’
03-07-2018
Novartis acquires gene therapy company
18-05-2018
Obencem / iStockphoto.com
Novartis has revealed plans to sell the dermatology business and generic US oral solids portfolios of its subsidiary Sandoz US to India-based Aurobindo for $900 million.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Novartis, Sandoz, Aurobindo, mergers and acquisitions, M&A, generics, dermatology, oral solids
